Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Pieczonka

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Prostate Cancer and Prostatic Diseases|October 8, 2020
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancerArif Hussain, Abhishek Tripathi, Christopher Pieczonka, et al.
Urology|July 1, 2014
Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapyHerbert James, Ilija Aleksic, Marc Nicolas Bienz, et al.
American Journal of Cancer Research|February 10, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studiesRushikesh Potdar, Benjamin A Gartrell, Robert Given, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
World Journal of Urology|November 15, 2023
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patientsStephen J Freedland, Sandhya Nair, Xiwu Lin, et al.
BJU International|September 10, 2022
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trialNeal D Shore, Arnulf Stenzl, Christopher Pieczonka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2022
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting AgentMark C Markowski, Ronald Tutrone, Christopher Pieczonka, et al.
The Prostate|August 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for cliniciansNeal D Shore, Charles G Drake, Daniel W Lin, et al.
European Urology|April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 TrialDavid P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
The Lancet. Oncology|October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Josep Piulats, Tilman Todenhöfer, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Prostate Cancer and Prostatic Diseases|October 8, 2020
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancerArif Hussain, Abhishek Tripathi, Christopher Pieczonka, et al.
Urology|July 1, 2014
Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapyHerbert James, Ilija Aleksic, Marc Nicolas Bienz, et al.
American Journal of Cancer Research|February 10, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studiesRushikesh Potdar, Benjamin A Gartrell, Robert Given, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
World Journal of Urology|November 15, 2023
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patientsStephen J Freedland, Sandhya Nair, Xiwu Lin, et al.
BJU International|September 10, 2022
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trialNeal D Shore, Arnulf Stenzl, Christopher Pieczonka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2022
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting AgentMark C Markowski, Ronald Tutrone, Christopher Pieczonka, et al.
The Prostate|August 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for cliniciansNeal D Shore, Charles G Drake, Daniel W Lin, et al.
European Urology|April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 TrialDavid P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
The Lancet. Oncology|October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Josep Piulats, Tilman Todenhöfer, et al.
Pageof 2